Monoclonal Antibody-Based Agents in Cancer Treatment: From Laboratory to the Clinic
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (15 December 2014) | Viewed by 10689
Special Issue Editor
Interests: therapeutic and diagnostic antibodies; cancer therapy; discovery of therapeutic targets
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the past 28 years, several monoclonal antibody-based drugs have been approved for the treatment of a wide range of human diseases and, in particular, human cancers. At present, 16 antibodies of murine, chimeric, humanised, and fully human formats have been approved for the treatment of cancer patients in the USA and European Union. In 2011, the top three best-selling cancer drugs were monoclonal antibodies, namely anti-CD20 rituximab, anti-VEGF bevacizumab, and anti-HER-2 trastuzumab with sales of $3 billion, $2.66 billion and $1.66 billion, respectively. In addition, hundreds of antibody-based products are currently at different stages of preclinical development or clinical trials.
This Special Issue of therapeutic antibodies will highlight these advances, some of the challenges (e.g., resistance to antibody therapy, the high cost of therapeutic antibodies), as well as future opportunities for more effective and routine usage of antibody-based products in the treatment of cancer patients. It will contain the latest original data and reviews of approved therapeutic antibodies, and other promising antibody-based products which are at different stages of clinical trials or preclinical development. The therapeutic potential of other antibody formats in cancer (e.g., shark antibodies, IgE antibodies, antibody fragments, conjugated-antibodies), and the usage of alternative strategies for the production of less expensive therapeutic antibodies, will also be covered in this issue.
Prof. Dr. Helmout Modjtahedi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- therapeutic antibodies
- naked antibodies
- fragmented therapeutic antibodies
- conjugated antibodies
- antibody in discovery of novel antigens
- IgE antibodies
- shark Antibodies
- antibodies in transgenic plants
- antibodies in transgenic animals
